Adaptive Biotechnologies (ADPT) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Fiserv president resigns, interim leaders named for financial unit
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results
November 10, 2020 4:10 PM ESTSEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2020.
Over the last quarter, we have demonstrated the unique capability of our platform to translate the immune response at scale into data that informs the development of best-in-class, differentiated diagnostic and therapeutic solutions, said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. This pandemic has... More
